Cargando…

Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer

INTRODUCTION: Stage IIB cervical cancer (CC) is an advanced stage CC with poor prognosis. Inflammatory response plays a crucial role in the development of CC, and systemic inflammatory indexes were related to the prognosis in several cancers. The objective of the study was to determine the prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yong-Xia, Chang, Jian-Ying, He, Ming-Yuan, Wang, He-Ran, Luo, Dai-Qin, Li, Feng-Hu, Li, Jie-Hui, Ran, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443385/
https://www.ncbi.nlm.nih.gov/pubmed/34539781
http://dx.doi.org/10.1155/2021/2939162
_version_ 1783753176547065856
author Li, Yong-Xia
Chang, Jian-Ying
He, Ming-Yuan
Wang, He-Ran
Luo, Dai-Qin
Li, Feng-Hu
Li, Jie-Hui
Ran, Li
author_facet Li, Yong-Xia
Chang, Jian-Ying
He, Ming-Yuan
Wang, He-Ran
Luo, Dai-Qin
Li, Feng-Hu
Li, Jie-Hui
Ran, Li
author_sort Li, Yong-Xia
collection PubMed
description INTRODUCTION: Stage IIB cervical cancer (CC) is an advanced stage CC with poor prognosis. Inflammatory response plays a crucial role in the development of CC, and systemic inflammatory indexes were related to the prognosis in several cancers. The objective of the study was to determine the prognostic value of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), basophil-to-lymphocyte ratio (BLR), and systemic inflammation response index (SIRI) as inflammatory indexes in patients with stage IIB CC. MATERIALS AND METHODS: A retrospective study was performed in 260 patients with stage IIB CC. PLR, NLR, MLR, BLR, and SIRI were obtained from routine blood tests. Prognosis information of the patients was acquired from regular clinical follow-up. Recurrence and response to therapy were determined through electronic medical records (EMRs). Correlations of the inflammatory indexes with overall survival (OS), progression-free survival (PFS), recurrence, and response to therapy were analyzed using SPSS version 26.0 software. RESULTS: Receiver operating characteristic (ROC) curve analyses suggested that NLR, MLR, and SIRI had better predictive value than PLR as well as BLR in the prognosis and recurrence risk. Both univariate and multivariate survival analyses showed that higher NLR and MLR were significantly associated with shorter OS as well as PFS, whereas SIRI was not an independent predictive factor of PFS. Chi-square test results revealed that increased NLR was significantly correlated with higher recurrence rate (P=0.046), and increased MLR showed significant correlation with elevated recurrence risk (P=0.002). Univariate and binary logistic regression analyses for response to therapy indicated that elevated NLR was associated with decreased complete remission (CR) rate (P=0.031), and the P value lost statistical significance while being adjusted by tumor size (P=0.108). CONCLUSIONS: For patients with stage IIB CC, both NLR and MLR are independent prognostic factors as well as risk factors for recurrence; NLR serves as a potential marker for therapeutic response.
format Online
Article
Text
id pubmed-8443385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84433852021-09-16 Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer Li, Yong-Xia Chang, Jian-Ying He, Ming-Yuan Wang, He-Ran Luo, Dai-Qin Li, Feng-Hu Li, Jie-Hui Ran, Li J Oncol Research Article INTRODUCTION: Stage IIB cervical cancer (CC) is an advanced stage CC with poor prognosis. Inflammatory response plays a crucial role in the development of CC, and systemic inflammatory indexes were related to the prognosis in several cancers. The objective of the study was to determine the prognostic value of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), basophil-to-lymphocyte ratio (BLR), and systemic inflammation response index (SIRI) as inflammatory indexes in patients with stage IIB CC. MATERIALS AND METHODS: A retrospective study was performed in 260 patients with stage IIB CC. PLR, NLR, MLR, BLR, and SIRI were obtained from routine blood tests. Prognosis information of the patients was acquired from regular clinical follow-up. Recurrence and response to therapy were determined through electronic medical records (EMRs). Correlations of the inflammatory indexes with overall survival (OS), progression-free survival (PFS), recurrence, and response to therapy were analyzed using SPSS version 26.0 software. RESULTS: Receiver operating characteristic (ROC) curve analyses suggested that NLR, MLR, and SIRI had better predictive value than PLR as well as BLR in the prognosis and recurrence risk. Both univariate and multivariate survival analyses showed that higher NLR and MLR were significantly associated with shorter OS as well as PFS, whereas SIRI was not an independent predictive factor of PFS. Chi-square test results revealed that increased NLR was significantly correlated with higher recurrence rate (P=0.046), and increased MLR showed significant correlation with elevated recurrence risk (P=0.002). Univariate and binary logistic regression analyses for response to therapy indicated that elevated NLR was associated with decreased complete remission (CR) rate (P=0.031), and the P value lost statistical significance while being adjusted by tumor size (P=0.108). CONCLUSIONS: For patients with stage IIB CC, both NLR and MLR are independent prognostic factors as well as risk factors for recurrence; NLR serves as a potential marker for therapeutic response. Hindawi 2021-09-08 /pmc/articles/PMC8443385/ /pubmed/34539781 http://dx.doi.org/10.1155/2021/2939162 Text en Copyright © 2021 Yong-Xia Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Yong-Xia
Chang, Jian-Ying
He, Ming-Yuan
Wang, He-Ran
Luo, Dai-Qin
Li, Feng-Hu
Li, Jie-Hui
Ran, Li
Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title_full Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title_fullStr Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title_full_unstemmed Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title_short Neutrophil-to-Lymphocyte Ratio (NLR) and Monocyte-to-Lymphocyte Ratio (MLR) Predict Clinical Outcome in Patients with Stage IIB Cervical Cancer
title_sort neutrophil-to-lymphocyte ratio (nlr) and monocyte-to-lymphocyte ratio (mlr) predict clinical outcome in patients with stage iib cervical cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443385/
https://www.ncbi.nlm.nih.gov/pubmed/34539781
http://dx.doi.org/10.1155/2021/2939162
work_keys_str_mv AT liyongxia neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT changjianying neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT hemingyuan neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT wangheran neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT luodaiqin neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT lifenghu neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT lijiehui neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer
AT ranli neutrophiltolymphocyterationlrandmonocytetolymphocyteratiomlrpredictclinicaloutcomeinpatientswithstageiibcervicalcancer